GlassScriptPhysician profile
Kelly Reid
NPI 1033706981
$7,991.15
in general payments reported to CMS, 2019-2025
33 companies · $2,399 in 2025
The $2,399 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $387 · 2022: $1,231 · 2023: $2,103 · 2024: $1,872 · 2025: $2,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,372.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,086.96 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $969.31 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $844.34 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $694.85 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $597.96 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $531.27 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $490.38 | 2022-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $348.05 | 2022-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $315.15 | 2022-2025 | Auvelity, Sunosi |
| Novo Nordisk INC | $282.71 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Ironshore Pharmaceuticals INC. | $253.39 | 2022-2024 | Jornay Pm |
| Corium, LLC | $219.85 | 2023-2025 | Azstarys |
| Lundbeck LLC | $203.82 | 2021-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $201.45 | 2022-2025 | Austedo Xr, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $186.45 | 2024-2025 | Cobenfy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $106.59 | 2022-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $83.59 | 2022 | |
| Indivior INC. | $73.70 | 2023-2024 | Perseris, Sublocade |
| Astrazeneca Pharmaceuticals LP | $69.97 | 2023-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $63.87 | 2024-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $56.50 | 2022-2023 | |
| Brainsway USA INC | $53.88 | 2021-2022 | |
| Exact Sciences Corporation | $35.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Currax Pharmaceuticals LLC | $29.35 | 2021 | |
| Harmony Biosciences LLC | $26.14 | 2024 | |
| Almatica Pharma LLC | $25.72 | 2024 | Loreev Xr |
| Alnylam Pharmaceuticals INC. | $25.40 | 2024 | Givlaari |
| Idorsia Pharmaceuticals US INC | $23.67 | 2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $22.34 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.98 | 2022 | |
| Sage Therapeutics, LLC | $19.94 | 2023 | |
| Collegium Pharmaceutical, INC. | $13.63 | 2025 | Jornay Pm |
| Owp Pharmaceuticals, INC. | $13.08 | 2024 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.